948 Results

People

  1. Kris
    Kris
  2. Kelsen
    Kelsen
  3. Motzer
    Motzer
  4. O'Reilly
    O'Reilly
  5. Saltz
    Saltz
  6. Tyson
    Tyson
  7. Gralla
    Gralla
  8. Hudis
    Hudis
  9. Scher
    Scher
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)
  7. Center for Hematologic Malignancies (109)
  8. Genitourinary Oncology Service (106)
  9. Nursing (101)
  10. Surgery (97)
  1. "vomiting"
Formats
  1. Journal Article (896)
  2. Review (27)
  3. Conference Paper (8)
  4. Editorial (6)
  5. Research Letter (4)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Book Section (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (633)
  2. Solid Tumor Oncology Division (507)
  3. Gastrointestinal Oncology Service (138)
  4. Survivorship Research (128)
  5. Hematologic Malignancies, Division of (127)
  6. Thoracic Oncology (112)

More Groups

People
  1. Mark Kris (70)
  2. David Kelsen (40)
  3. Robert Motzer (39)
  4. Eileen O'Reilly (30)
  5. Leonard Saltz (30)
  6. Leslie Tyson (28)

More People

Years
  1. 2025 (25)
  2. 2024 (63)
  3. 2023 (44)
  4. 2022 (32)
  5. 2021 (15)
  6. 2020 (50)

More Years

Publications
  1. Journal of Clinical Oncology (90)
  2. Cancer (47)
  3. Clinical Cancer Research (44)
  4. Lancet Oncology (38)
  5. Gynecologic Oncology (31)
  6. Cancer Treatment Reports (26)

More Publications

Publishers
  1. Elsevier Inc. (145)
  2. American Society of Clinical Oncology (92)
  3. Elsevier Science, Inc. (74)
  4. Springer (72)
  5. Oxford University Press (64)
  6. Wiley Blackwell (63)

More Publishers

Results (948)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Disease course and outcomes of COVID-19 among hospitalized patients with gastrointestinal manifestations
    Journal Article

    Laszkowska, M.; Faye, A. S.; Kim, J.; Truong, H.; Silver, E. R.; Ingram, M.; May, B.; Ascherman, B.; Bartram, L.; Zucker, J.; more...
    Clinical Gastroenterology and Hepatology (2021)

    Fulltext@MSK | Save
  • EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
    Review

    Julia, E.; Salles, G.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
    Journal Article

    Harding, J. J.; Do, R. K.; Yaqubie, A.; Cleverly, A.; Zhao, Y.; Gueorguieva, I.; Lahn, M.; Benhadji, K. A.; Kelley, R. K.; Abou-Alfa, G. K.
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Getting blood out of a stone: Identification and management of patients with poor hematopoietic cell mobilization
    Review

    Chen, J.; Lazarus, H. M.; Dahi, P. B.; Avecilla, S.; Giralt, S. A.
    Blood Reviews (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Journal Article

    Lee, N. Y.; Ferris, R. L.; Psyrri, A.; Haddad, R. I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P. M. H.; Lin, J. C.; Razaq, M. A.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
    Journal Article

    Choueiri, T. K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
    Journal Article

    DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; Patel, P. A.; Raffoux, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma
    Journal Article

    El Dika, I.; Mayer, R. J.; Venook, A. P.; Capanu, M.; LaQuaglia, M. P.; Kobos, R.; O'Neill, A. F.; Chou, J. F.; Ly, M.; Ang, C.; more...
    The Oncologist (2020)

    Fulltext@MSK | Save